Goldman Sachs’s Akcea Therapeutics Inc AKCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-73,522
| Closed | -$1.33M | – | 5889 |
|
|
2020
Q3 | $1.33M | Sell |
73,522
-39,275
| -35% | -$557K | ﹤0.01% | 3871 |
|
|
2020
Q2 | $1.54M | Buy |
112,797
+46,232
| +69% | +$713K | ﹤0.01% | 3637 |
|
|
2020
Q1 | $952K | Sell |
66,565
-18,979
| -22% | -$312K | ﹤0.01% | 3796 |
|
|
2019
Q4 | $1.45M | Buy |
85,544
+21,651
| +34% | +$403K | ﹤0.01% | 3881 |
|
|
2019
Q3 | $983K | Buy |
63,893
+12,621
| +25% | +$269K | ﹤0.01% | 4045 |
|
|
2019
Q2 | $1.2M | Sell |
51,272
-765
| -1% | -$18.9K | ﹤0.01% | 3871 |
|
|
2019
Q1 | $1.47M | Buy |
52,037
+1,470
| +3% | +$42.8K | ﹤0.01% | 3831 |
|
|
2018
Q4 | $1.52M | Buy |
50,567
+3,734
| +8% | +$105K | ﹤0.01% | 3700 |
|
|
2018
Q3 | $1.64M | Sell |
46,833
-17,270
| -27% | -$523K | ﹤0.01% | 3735 |
|
|
2018
Q2 | $1.52M | Buy |
64,103
+20,326
| +46% | +$485K | ﹤0.01% | 3800 |
|
|
2018
Q1 | $1.12M | Buy |
43,777
+9,314
| +27% | +$200K | ﹤0.01% | 3980 |
|
|
2017
Q4 | $598K | Buy |
+34,463
| New | +$676K | ﹤0.01% | 4690 |
|
Goldman Sachs's AKCA Position: Q4 2020 in Review
Goldman Sachs sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 73,522 shares — an estimated $1.33M sold.
Goldman Sachs first reported a position in AKCA in Q4 2017 and held it in 12 quarters. The position peaked at $1.64M in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.
- Goldman Sachs reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
- Goldman Sachs sold 73,522 Akcea Therapeutics Inc shares in Q4 2020, an estimated $1.33M.
- Goldman Sachs first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 12 quarters.
- Goldman Sachs's Akcea Therapeutics Inc position peaked at $1.64M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.
Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.